Caudate volume as an outcome measure in clinical trials for Huntington’s disease: a pilot study
- 15 December 2003
- journal article
- Published by Elsevier in Brain Research Bulletin
- Vol. 62 (2) , 137-141
- https://doi.org/10.1016/j.brainresbull.2003.09.005
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Therapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's DiseaseJournal of Neuroscience, 2002
- Longitudinal study of brain morphology in first episode schizophreniaBiological Psychiatry, 2001
- Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's diseaseMovement Disorders, 2000
- Influence of lamotrigine on progression of early Huntington diseaseNeurology, 1999
- Structural Evaluation of the Prefrontal Cortex in SchizophreniaAmerican Journal of Psychiatry, 1998
- Longitudinal change in basal ganglia volume in patients with Huntington's diseaseNeurology, 1997
- Basal Ganglia Volume and Proximity to Onset in Presymptomatic Huntington DiseaseArchives of Neurology, 1996
- A controlled trial of remacemide hydrochloride in Huntington's diseaseMovement Disorders, 1996
- Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the catBrain Research, 1994
- Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's diseaseAnnals of Neurology, 1992